Research Feature - Remission Outcomes Following CBT or Supportive Psychotherapy for BDD

Off

Featuring:

Hilary Weingarden, PhD
and
Professional
ADAA Research - CBT or Supportive Psychotherapy for BDD
Thursday, July 01, 2021 12:00 pm
- 12:00 pm ET
Category
Treatment

Research Feature - Remission Outcomes Following CBT or Supportive Psychotherapy for BDD

#ADAA2021Virtual Donald F. Klein Runner Up Research Presentation

Although remission rates are key efficacy benchmarks that patients are likely to ask for before beginning psychotherapy, little data exist on remission rates after psychotherapy for body dysmorphic disorder (BDD). This webinar presents remission rates following 24 weeks of therapist-delivered cognitive behavioral therapy (CBT) or supportive psychotherapy (SPT) for BDD (N=120), using secondary data from a large, randomized controlled trial (Wilhelm et al., 2019). The webinar also covers remission outcomes at 6-month follow-up, including rates of delayed remission, sustained remission, no remission at any time point, and recurrence by treatment condition. Finally, the webinar covers changes in broader mental health outcomes - depression severity, functional impairment, BDD-related insight, and quality of life - among remitters compared to non-remitters at treatment endpoint. Results are presented with an eye toward clinical implications. 

 


2022 Donald F. Klein Early Career Investigator Award

ADAA offers an annual award to an early career investigator for the best original research paper on neurobiology, psychopharmacology, psychosocial treatments, or experimental psychopathology of anxiety disorders and depression. This award is named for Donald F. Klein, MD (1928-2019), who revolutionized psychiatric thinking through his discovery in the early 1960s that imipramine, a recently developed psychotropic medication, was effective in blocking panic attacks.

 

Click Here to Receive 2022 Award Information

Click Here to Begin Your 2022 Submission 

Presenter(s) Biography

Hilary Weingarden, PhD

Hilary Weingarden

Member Since 2018

 

​“I first became involved in ADAA in 2018, when I attended my first ADAA conference. I initially got involved because the conference was so highly recommended to me by my colleagues. ADAA is a unique organization that joins together professionals with a range of different professional backgrounds, who are all focused on similar clinical domains. Because of that, the scope and content of the conferences feel very relevant. I also appreciate that you can attend the conference and expand your clinical and research skillsets in one place.”

 

“ADAA offers a community of professionals with complementary skills and expertise both clinically and in research.“

 

“I was recently promoted to Assistant Professor at Harvard Medical School, in June of 2020.  Additionally, I was awarded a K23 Career Development Award from NIMH in Sept 2019, to fund my research and training focused on smartphone-based detection of high-risk negative emotion states and prediction of related adverse outcomes (i.e., suicidal ideation, substance use) in participants with body dysmorphic disorder. I was selected as runner-up for the 2021 ADAA Donald F. Klein Early Career Investigator Award and I received a 2019 Rising Star Award from the Association for Psychological Science (APS).”

 

Hilary Weingarden, PhD is an Assistant Professor at Harvard Medical School (HMS) and a staff psychologist in the Center for OCD and Related Disorders (CORD) at Massachusetts General Hospital (MGH). Dr. Weingarden received her bachelor's degree from Tufts University and her PhD in clinical psychology from George Mason University. She completed her clinical internship and postdoctoral training at MGH/HMS and is a licensed psychologist in the state of Massachusetts. Dr. Weingarden's research is focused on cognitive and emotional risk factors for adverse outcomes such as suicide risk in OCD and body dysmorphic disorder (BDD). Her research also focuses on applying technology to enhance assessment of and interventions for OCD and related disorders. Her work is currently supported by a Career Development Award (K23) from the National Institute of Mental Health. In addition to NIMH, Dr. Weingarden's work has been funded as Principal Investigator or co-Investigator by Harvard Medical School and industry collaborations, and she was a 2019 recipient of the Association for Psychological Science's (APS) Rising Star Award. In addition to her work at MGH, Dr. Weingarden has a private practice where she provides evidence-based psychological treatments for adults with OCD and related disorders. 

and
Professional Post
On
CE/CME Accreditation Statement

ADAA Continuing Education Credits for Live and On-Demand Programming

Learners complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available.  If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Some ADAA professional webinars focused on diversity or cultural competency subject matter are eligible for the Cross-Culture Competency Diversity Credit. If a webinar is eligible for this credit, it will be reflected on your credit certificate.

All continuing education credits are provided through Amedco, LLC. Learn more about the CE/CME accreditation information here.